Relmada Therapeutics (RLMD) Stock
Clinical stage biotech developing pain and brain treatments. Here's the price, business snapshot, and what's worth knowing about Relmada Therapeutics in August 2026.
Relmada Therapeutics Inc (RLMD) is a small-cap, clinical-stage biotechnology company developing treatments in the central nervous system and pain space. With a market capitalisation around $74m, it is primarily value-driven by clinical trial milestones, regulatory reviews and potential partnerships or licensing deals. For investors, key considerations include the binary nature of clinical outcomes, a likely need for additional financing to fund development, and limited commercial revenue at this stage. The share price can be highly volatile and sensitive to trial data, analysts’ updates and broader biotech sector moves. Researching trial designs, timelines, cash runway and management experience can help form a view. This summary is educational and not investment advice; biotech stocks can offer significant upside but also substantial risk and loss of capital. Ensure any decision aligns with your risk tolerance and consider diversified exposure rather than relying on a single clinical-stage name.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying RELMADA's stock, expecting its price to rise significantly.
Financial Health
Relmada Therapeutics is showing solid cash flow and book value, indicating strong financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial Milestones Matter
Clinical readouts and regulatory steps tend to drive price moves; positive data can boost prospects but results can also disappoint.
Binary Outcomes Risk
Development-stage outcomes are often binary — success or failure — creating high volatility. Consider diversification to manage risk.
Funding And Partnerships
Cash runway and strategic partnerships can alter the company’s path; watch financing announcements that may dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
